Moreover, the idea of SMURF1 inhibition in patients has gained interest as a potential therapeutic strategy in other clinical contexts including pulmonary hypertension [23,24] and macular degeneration [25]. This evidence concerns the gene SMURF1 and pulmonary hypertension.